PCN8 COST-EFFECTIVENESS ANALYSIS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV GENERIC PAMIDRONATE FOR BONE METASTASES FROM BREAST CANCER IN PATIENTS RECEIVING ORAL HORMONAL THERAPY IN THE UK
Abstract
Authors
E De Cock J Hutton P Barrett-Lee P Canney JJ Body M Neary GJ Lewis